S
SAB Biotherapeutics, Inc. (SABS)
NCM – Real vaqt narxi. Valyuta: USD
3.62
-0.10 (-2.69%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
3.62
-0.10 (-2.69%)
Yopilishda: May 12, 2026, 4:00 PM EDT
SAB Biotherapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda immunitet tizimi buzilishlari va yuqumli kasalliklarni davolash uchun inson polikonal immunoterapiya antitelalarini ishlab chiqishga qaratilgan. Uning asosiy mahsulot nomzodi SAB-142 bo'lib, bu avtoimmun 1-toifa diabetni davolash uchun klinik rivojlanishdagi potentsial kasallikni o'zgartiruvchi va qayta dozalash mumkin bo'lgan immunoterapiya bo'lib, 2b bosqichdagi klinik sinovlarda. Kompaniya 2014-yilda tashkil etilgan va Floridadagi Mayami-Bich shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Alexandra Kropotova M.B.A., M.D. | Executive VP & Chief Medical Officer |
| Dr. Carlos N. Carillo M.Sc., Ph.D. | Senior Vice President of Regulatory Affairs |
| Dr. Christoph Bausch M.B.A., Ph.D. | Executive VP & COO |
| Dr. Eddie Joe Sullivan Ph.D. | Co-Founder, President & Director |
| Mr. Samuel J. Reich | CEO & Director |
| Ms. Angie Parizek | Senior Vice President of Clinical Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 10-Q | sabs-20260331.htm |
| 2026-05-04 | 8-K | sabs-20260428.htm |
| 2026-04-22 | 8-K | sabs-20260422.htm |
| 2026-03-31 | S-8 | sabs-20260331.htm |
| 2026-03-19 | 8-K | sabs-20260317.htm |
| 2026-03-10 | 8-K | sabs-20260310.htm |
| 2026-03-09 | 10-K | sabs-20251231.htm |
| 2026-01-12 | 8-K | sabs-20260112.htm |
| 2026-01-07 | 8-K | sabs-20260105.htm |
| 2025-12-29 | S-3 | sabs-20251229.htm |
| Ms. Catherine DeRose | Vice President of Human Resources |
| Ms. Cristi Barnett | Vice President of Investor Relations & Corporate Communications |
| Ms. Hua Wu Ph.D. | Senior Vice President of Product Development |
| Ms. Lucy To | Executive VP & CFO |